[go: up one dir, main page]

MX2021006364A - Compuestos heterociclicos para el tratamiento de la epilepsia. - Google Patents

Compuestos heterociclicos para el tratamiento de la epilepsia.

Info

Publication number
MX2021006364A
MX2021006364A MX2021006364A MX2021006364A MX2021006364A MX 2021006364 A MX2021006364 A MX 2021006364A MX 2021006364 A MX2021006364 A MX 2021006364A MX 2021006364 A MX2021006364 A MX 2021006364A MX 2021006364 A MX2021006364 A MX 2021006364A
Authority
MX
Mexico
Prior art keywords
seizure
epilepsy
treatment
heterocyclic compounds
diagnosing
Prior art date
Application number
MX2021006364A
Other languages
English (en)
Inventor
Nobuaki Ito
Tomoichi Shinohara
Shin Iwata
Kenta Arai
Masaki Suzuki
Takuya Chiba
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2021006364A publication Critical patent/MX2021006364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención provee un compuesto heterocíclico novedoso representado por la fórmula [I] y una sal del mismo, en donde los símbolos son como se define en la especificación, que es útil para tratar, prevenir y/o diagnosticar enfermedades convulsivas que incluyen crisis epiléptica o crisis convulsiva (que incluyen crisis multirresistente a fármacos, crisis refractaria, crisis sintomática aguda, convulsión febril y estado epiléptico), así como también el uso medicinal del mismo. (ver Fórmula) [Fórmula I].
MX2021006364A 2018-11-30 2019-11-29 Compuestos heterociclicos para el tratamiento de la epilepsia. MX2021006364A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018224724 2018-11-30
PCT/JP2019/046879 WO2020111263A1 (en) 2018-11-30 2019-11-29 Heterocyclic compounds for the treatment of epilepsy

Publications (1)

Publication Number Publication Date
MX2021006364A true MX2021006364A (es) 2021-08-11

Family

ID=68887096

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2021006364A MX2021006364A (es) 2018-11-30 2019-11-29 Compuestos heterociclicos para el tratamiento de la epilepsia.
MX2024001270A MX2024001270A (es) 2018-11-30 2021-05-28 Compuestos heterociclicos para el tratamiento de la epilepsia.
MX2024012891A MX2024012891A (es) 2018-11-30 2021-05-28 Compuestos heterociclicos para el tratamiento de la epilepsia

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024001270A MX2024001270A (es) 2018-11-30 2021-05-28 Compuestos heterociclicos para el tratamiento de la epilepsia.
MX2024012891A MX2024012891A (es) 2018-11-30 2021-05-28 Compuestos heterociclicos para el tratamiento de la epilepsia

Country Status (17)

Country Link
US (2) US12391674B2 (es)
EP (1) EP3887358A1 (es)
JP (2) JP7539377B2 (es)
KR (1) KR20210097148A (es)
CN (1) CN113166076A (es)
AU (2) AU2019390907B2 (es)
BR (1) BR112021006222A2 (es)
CA (1) CA3118071A1 (es)
EA (1) EA202191473A1 (es)
IL (3) IL318120A (es)
MX (3) MX2021006364A (es)
MY (1) MY210184A (es)
PH (1) PH12021551233A1 (es)
SG (1) SG11202104374WA (es)
TW (2) TWI853857B (es)
WO (1) WO2020111263A1 (es)
ZA (1) ZA202103106B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202104374WA (en) * 2018-11-30 2021-05-28 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
WO2021231933A1 (en) * 2020-05-15 2021-11-18 Neucyte Pharmaceuticals Anti-epileptic pharmaceutical compositions and use thereof
CN117126133A (zh) * 2023-08-14 2023-11-28 中国海洋大学 一种化合物及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2414612A1 (de) 1974-03-26 1975-10-16 Bayer Ag 1-aryluracile, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
US4239888A (en) * 1974-11-04 1980-12-16 Pfizer Inc. 1-Phenyluracils
HUP0104171A3 (en) * 1998-11-17 2002-04-29 Ihara Chemical Ind Co Pyrimidinylbenzimidazole and triatinylbenzimidazole derivatives, intermediates and use as agricultura/horticultural fungicides
JP2002193710A (ja) * 2000-12-25 2002-07-10 Kumiai Chem Ind Co Ltd ピリミジン又はトリアジン誘導体及び農園芸用殺菌剤
AU2003249812A1 (en) 2002-07-18 2004-02-09 Queen's University At Kingston Dihydrouracil compounds as anti-ictogenic or anti-epileptogenic agents
WO2004029204A2 (en) 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
AR077999A1 (es) * 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
BR112012015868A2 (pt) * 2009-12-11 2017-06-20 Autifony Therapeutics Ltd derivados de imidazolidinadiona
AU2011207229B2 (en) 2010-01-25 2015-02-12 Chdi Foundation, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2012076877A1 (en) 2010-12-06 2012-06-14 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
EP2718285B1 (en) 2011-06-07 2016-03-16 Autifony Therapeutics Limited Hydantoin derivatives as kv3 inhibitors
CN103841829A (zh) 2011-07-28 2014-06-04 Chdi基金会股份有限公司 某些犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CA2856654C (en) 2011-12-06 2020-03-31 Autifony Therapeutics Limited Hydantoin derivatives useful as kv3 inhibitors
CN104334547B (zh) * 2012-05-22 2017-06-06 奥蒂福尼疗法有限公司 作为kv3抑制剂的三唑类
KR20180052635A (ko) 2015-09-18 2018-05-18 가켄 세이야쿠 가부시키가이샤 바이아릴 유도체 및 이를 포함하는 약제
GB201521751D0 (en) 2015-12-10 2016-01-27 Autifony Therapeutics Ltd Novel uses
JP6469272B2 (ja) 2017-03-01 2019-02-13 科研製薬株式会社 ビアリール誘導体又はその塩からなる医薬
KR102002446B1 (ko) 2017-03-16 2019-07-22 재단법인 대구경북첨단의료산업진흥재단 TGase 2 억제제로서의 퀴놀린-5,8-디온 유도체 및 이를 포함하는 약제학적 조성물
WO2018220762A1 (ja) 2017-05-31 2018-12-06 大塚製薬株式会社 ピリミジン化合物
SG11202104374WA (en) * 2018-11-30 2021-05-28 Otsuka Pharma Co Ltd Heterocyclic compounds for the treatment of epilepsy
JP6870064B2 (ja) 2018-11-30 2021-05-12 大塚製薬株式会社 ピリミジン化合物の医薬用途
JP2021187859A (ja) 2020-05-29 2021-12-13 大塚製薬株式会社 複素環化合物の医薬用途

Also Published As

Publication number Publication date
AU2025202599A1 (en) 2025-05-15
TW202039446A (zh) 2020-11-01
JP7539377B2 (ja) 2024-08-23
US12391674B2 (en) 2025-08-19
AU2019390907B2 (en) 2025-05-08
TWI853857B (zh) 2024-09-01
AU2019390907A1 (en) 2021-05-27
US20210403456A1 (en) 2021-12-30
KR20210097148A (ko) 2021-08-06
SG11202104374WA (en) 2021-05-28
TW202448474A (zh) 2024-12-16
TWI877067B (zh) 2025-03-11
PH12021551233A1 (en) 2021-12-06
CN113166076A (zh) 2021-07-23
JP2024160219A (ja) 2024-11-13
ZA202103106B (en) 2022-10-26
MY210184A (en) 2025-08-31
US20250304558A1 (en) 2025-10-02
IL318120A (en) 2025-02-01
EA202191473A1 (ru) 2021-08-27
IL311021A (en) 2024-04-01
MX2024001270A (es) 2024-02-15
TW202426426A (zh) 2024-07-01
JP2022509848A (ja) 2022-01-24
MX2024012891A (es) 2024-11-08
JP7765556B2 (ja) 2025-11-06
BR112021006222A2 (pt) 2021-07-06
WO2020111263A1 (en) 2020-06-04
CA3118071A1 (en) 2020-06-04
EP3887358A1 (en) 2021-10-06
IL282700A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
SG176628A1 (en) Aminopyrrolidinone derivatives and uses thereof
PH12021551233A1 (en) Heterocyclic compounds for the treatment of epilepsy
EA201891565A1 (ru) Соединения и композиции для лечения состояний, ассоциированных с активностью sting
MX389672B (es) Inhibidores de ssao de aminopirimidina
EA201591614A1 (ru) Соединения 1,3-оксазин-2-амина, конденсированные с перфторированным циклопропилом, в качестве ингибиторов бета-секретазы и способы их применения
UY31803A (es) Compuesto cristalino
MD3221298T2 (ro) Derivați ai 4-oxo-3,4-dihidro-1,2,3-benzotriazinei ca modulatori a GPR139
EA202190395A1 (ru) Замещенные гетероарилом сульфонамидные соединения и их применение в качестве терапевтических средств
MX389142B (es) Compuestos espiro triciclicos.
MX2016008624A (es) Inhibidores de serina/treonina cinasa.
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
MX377293B (es) Pirrolamidas como inhibidores de la integrina alfa v.
PH12021550449A1 (en) 2,6-diamino pyridine compounds.
SG10201900144TA (en) Pyridone derivative having tetrahydropyranylmethyl group
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
ATE548032T1 (de) Verwendung von chlorguanabenzderivaten zur behandlung von mit polyglutaminexpansion assoziierten erkrankungen
MX2015011180A (es) Derivados de aril sulfamida y sulfamato como moduladores del receptor huerfano relacionado con el receptor del retinoide (porc).
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
JOP20200304A1 (ar) مركبات بنزينسلفوناميد واستخدامها كعوامل علاجية
PH12019502639A1 (en) Pyrimidine compound
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
EA201891688A1 (ru) Адамантановое производное и его применение
MX2019004200A (es) Terapia de combinacion.
MY198328A (en) Adamantylmethylamine Derivative and use Thereof as Pharmaceutical